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In a significant proportion of patients pain persists despite
sophisticated analgesic therapy. In addition, current avail-
able treatments provide sufficient pain relief only in a frac-
tion of chronic pain patients. This triggers intensive
research and drug development activities. The study of the
genetic regulation of pain and its inhibition is thereby con-
sidered as a key approach to the development of effective
treatments. Inherent parts of this approach are, besides
changes in the function of the gene products due to
genetic variants, alterations in the expression of pain-rele-
vant genes due to genetic variants at sites relevant for
gene transcription, splicing or DNA stability. Moreover,
mechanisms of gene expression control, which emerge
from several independent lines of contemporary research,
point at so far unappreciated complexity of gene expres-
sion control exceeding current paradigms. This involves
micro RNA control, that according to novel analysis acts
on all levels of gene expression including transcriptional
fine-tuning, mRNA processing up to translation, which
form together with classical epigenetic mechanisms
including DNA methylation and histone modifications a
regulatory apparatus of pain gene expression. Novel
research results clearly indicate that genetics and epige-
netics not only affect the pain phenotype and treatment,
but the interactions with the genome are bidirectional.
Thus, several lines of research evidence point at a high
complexity of the genetic control of pain and it is increas-
ingly recognized that this complexity of pain has to be
addressed. These developments are accompanied by inten-
sive methodological progresses in modern bioinformatics
that increasingly enable the comprehension and utilization
of the complexity of the genetic control of pain and its
inhibition. Examples of these developments are the exploi-
tations of knowledge base information enabling the identi-
fication of relevant biological processes addressed by pain
relevant genetic or epigenetic mechanisms. Moreover, ana-
lyses of pain phenotypes distributions allow identifying the
underlying molecular bases, or may be used to classify
pain patients for patterns of symptoms, which facilitates
the association of complex pain-relevant genotypes. These
developments promise, perhaps for the first time optimis-
tically, a major step toward the understanding of the com-
plexity of pain and the development of effective
individualized treatments.
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